Bharat Parenterals Ltd (BPLPHARMA) is currently trading at 1,532.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Arisinfra Solutions Limited is an asset-light construction materials and services platform that aggregates suppliers, supplies construction materials across multiple categories, provides contract manufacturing and value-added services, and supports project lifecycle delivery through technology-enabled logistics and execution capabilities for developers and contractors. Q3 FY26 was the company’s strongest quarter with Total Income of ₹272.5 crore, Revenue from Operations of ₹270.8 crore (49% YoY, 12% QoQ), EBITDA of ₹30 crore (106% YoY) and Reported PAT of ₹18.3 crore, reflecting improved mix, tighter working capital and disciplined cost management driving material margin expansion. Arisinfra is shifting mix from pure supply to execution-linked and services revenue: Contract Manufacturing now contributes 44% and services 9% of revenue YTD FY26, while Aggregates and RMC categories have expanded meaningfully, reflecting a strategic move toward execution and higher-value supply offerings. Balance sheet and working capital metrics show strengthening operational discipline: NWC days reduced to 74 YTD, DSO improved to 118 days, DPO extended to 44 days, cash balance stands at ₹185 crore and net worth at ₹718 crore, supporting repeat institutional engagements and selective, capital-efficient expansion. Strategic commercial developments include appointment as strategic partner for Amogaya Adorit and a consulting mandate from Transcon, plus an MoU with JS Infra and a ₹35 crore asphalt order via subsidiary Buildmex, signalling targeted entry into road infrastructure materials and broader execution-led services.

Over the past 52 weeks, Bharat Parenterals Ltd has traded between a low of ₹880.25 and a high of ₹1,593.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bharat Parenterals Ltd has a market capitalization of approximately 1,085.48. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bharat Parenterals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -36.19 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,085.48 Cr, Bharat Parenterals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bharat Parenterals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bharat Parenterals Ltd is -36.19. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.